Correction to: Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL
Gorde:
Egile Nagusiak: | G. Biolcati (Egilea), S. Hanneken (Egilea), E. I. Minder (Egilea), N. J. Neumann (Egilea), J. H. P. Wilson (Egilea), P. J. Wolgen (Egilea), D. J. Wright (Egilea), A. J. Lloyd (Egilea) |
---|---|
Formatua: | Liburua |
Argitaratua: |
SpringerOpen,
2021-08-01T00:00:00Z.
|
Gaiak: | |
Sarrera elektronikoa: | Connect to this object online. |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Antzeko izenburuak
-
Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL
nork: G. Biolcatti, et al.
Argitaratua: (2021) -
Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice
nork: Jasmin Barman-Aksözen, et al.
Argitaratua: (2017) -
Acquired erythropoietic protoporphyria secondary to myelodysplastic syndrome: from mythology to oncologyAcquired Erythropoietic Protoporphyria Secondary to Myelodysplastic Syndrome: From Mythology to Oncology
nork: Mirjana Urosevic-Maiwald, et al.
Argitaratua: (2024) -
Erythropoietic Protoporphyria in a Japanese Population
nork: Megumi Mizawa, et al.
Argitaratua: (2019) -
Illuminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria
nork: Katelyn E. Madigan, et al.
Argitaratua: (2023)